Cogent Biosciences files for USD 400 million at-the-market stock offering

• Cogent Biosciences set an at-the-market equity offering of up to USD 400 million under its sales agreement with Guggenheim Securities.
• Shares will be sold from time to time at market prices through or to Guggenheim Securities, acting as agent or principal.
• The program is being conducted under the company’s automatic shelf registration statement on Form S-3ASR filed on Nov. 7, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342695), on August 10, 2026, and is solely responsible for the information contained therein.